While 25% (₹9.98 Cr) of the amount, will be disbursed after the closing of the agreement, the remaining 75% (₹29.9 Cr) will be paid in three equal tranches between 2027 and 2029 Post the transaction, ...

Info Edge has approved the acquisition of the remaining 45.36% stake in Coding Ninjas from the edtech platform's founders for about Rs 39.91 crore, a move that will make the company a wholly owned ...

It’s been three-and-a-half years since generative AI exploded onto the scene. In this past year, progress has continued its relentless pace: Vibe coding took off, companies embraced agentic workflows, ...

If you’ve driven on the far western edge of the city lately, you’ve likely noticed that Amazon and Shamrock Foods have a new neighbor. That neighbor is Array Technologies, a publicly traded renewable ...

This article is part of AI Week. Since the start of the current wave of excitement around generative AI, coding has been viewed as a field that is ripe for implementation of the tech. After all, the ...

Abstract: High-level Synthesis (HLS) eases hardware design by offering a higher level of abstraction. However, high-level programming concepts, such as recursion, are costly to synthesize, if at all ...

Developers are navigating confusing gaps between expectation and reality. So are the rest of us. Depending who you ask, AI-powered coding is either giving software developers an unprecedented ...

The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. After ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...